OAKLAND, Calif. — Electricity is still hot.
The much-hyped field of “electroceuticals” — which involves zapping nerves with tiny electrical pulses to treat disease — got another injection of funds late last month with a $30 million investment round for startup SetPoint Medical.
Major medical device companies Medtronic and Boston Scientific kicked in funding, as did several venture funds. Global pharma giant GlaxoSmithKline has also invested in SetPoint.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect